奥利司他对比二甲双胍降低超体质量或肥胖患者体质量疗效和安全性的Meta分析(5)
[17] OLSZANECKA-GLINIANOWICZ M，DABROWSKI P，KOCELAK P，et al. Long-term inhibition of intestinal lipase by orlistat improves release of gut hormones increasing satiety in obese women[J]. Pharmacol Rep，2013，65(3)：666-671.
[18] DPP GROUP. Long-term safety，tolerability，and weight loss associated with metformin in the diabetes prevention program outcomes study[J]. Diabetes Care，2012，35(4)：731-737.
[19] MALIN SK，KASHYAP SR. Effects of metformin on weight loss：potential mechanisms[J]. Current Opinion in Endocrinology Diabetes & Obesity，2014，21(5)：323- 329.
[20] IGEL LI，SINHA A，SAUNDERS KH，et al. Metformin：an old therapy that deserves a new indication for the treatment of obesity[J]. Curr Atheroscler Rep，2016，18(4)：16.
[21] TAN MH，ALQURAINI H，MIZOKAMI-STOUT K，et al. Metformin：from research to clinical practice[J]. Endocrinology & Metabolism Clinics of North America，2016，45(4)：819-843.
[22] BILLA E，KAPOLLA N，NICOPOULOU SC，et al. Metformin administration was associated with a modification of LH，prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome[J]. Gynecol Endocrinol，2009，25(7)：427-434.
[23] PANIDIS D，TZIOMALOS K，PAPADAKIS E，et al. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome：impact on metabolism and fertility[J]. Endocrine，2013，44(3)：583-590.
[24] 魏春燕，蘇娜，徐珽.药物治疗超重和肥胖患者的国内外研究进展[J].中国药房，2014，25(42)：4003-4006.
[25] DOUGLAS IJ，LANGHAM J，BHASKARAN K，et al. Orlistat and the risk of acute liver injury：self controlled case series study in UK clinical practice research datalink[J]. BMJ，2013.DOI：10.1136/bmj.f1936.
[26] WEIR MA，BEYEA MM，GOMES T，et al. Orlistat and acute kidney injury：an analysis of 953 patients[J]. Arch Intern Med，2011，171(7)：703-704.
[27] HALPERN B，HALPERN A. Safety assessment of FDA- approved (orlistat and lorcaserin) anti-obesity medications[J]. Expert Opinion on Drug Safety，2015，14(2)：305- 315.
(收稿日期：2017-08-27 修回日期：2018-01-08)
(编辑：刘明伟), http://www.100md.com(刘永健 李凌鸥 程菲菲 刘玉婷 魏洁 刘东方)
[18] DPP GROUP. Long-term safety，tolerability，and weight loss associated with metformin in the diabetes prevention program outcomes study[J]. Diabetes Care，2012，35(4)：731-737.
[19] MALIN SK，KASHYAP SR. Effects of metformin on weight loss：potential mechanisms[J]. Current Opinion in Endocrinology Diabetes & Obesity，2014，21(5)：323- 329.
[20] IGEL LI，SINHA A，SAUNDERS KH，et al. Metformin：an old therapy that deserves a new indication for the treatment of obesity[J]. Curr Atheroscler Rep，2016，18(4)：16.
[21] TAN MH，ALQURAINI H，MIZOKAMI-STOUT K，et al. Metformin：from research to clinical practice[J]. Endocrinology & Metabolism Clinics of North America，2016，45(4)：819-843.
[22] BILLA E，KAPOLLA N，NICOPOULOU SC，et al. Metformin administration was associated with a modification of LH，prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome[J]. Gynecol Endocrinol，2009，25(7)：427-434.
[23] PANIDIS D，TZIOMALOS K，PAPADAKIS E，et al. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome：impact on metabolism and fertility[J]. Endocrine，2013，44(3)：583-590.
[24] 魏春燕，蘇娜，徐珽.药物治疗超重和肥胖患者的国内外研究进展[J].中国药房，2014，25(42)：4003-4006.
[25] DOUGLAS IJ，LANGHAM J，BHASKARAN K，et al. Orlistat and the risk of acute liver injury：self controlled case series study in UK clinical practice research datalink[J]. BMJ，2013.DOI：10.1136/bmj.f1936.
[26] WEIR MA，BEYEA MM，GOMES T，et al. Orlistat and acute kidney injury：an analysis of 953 patients[J]. Arch Intern Med，2011，171(7)：703-704.
[27] HALPERN B，HALPERN A. Safety assessment of FDA- approved (orlistat and lorcaserin) anti-obesity medications[J]. Expert Opinion on Drug Safety，2015，14(2)：305- 315.
(收稿日期：2017-08-27 修回日期：2018-01-08)
(编辑：刘明伟), http://www.100md.com(刘永健 李凌鸥 程菲菲 刘玉婷 魏洁 刘东方)